Compare SELF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | ALXO |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 68.3M |
| IPO Year | 1997 | 2020 |
| Metric | SELF | ALXO |
|---|---|---|
| Price | $5.19 | $2.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 27.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 5.57% | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $12,530,280.00 | N/A |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $34.40 | ★ N/A |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $4.73 | $0.41 |
| 52 Week High | $5.83 | $2.66 |
| Indicator | SELF | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 54.46 |
| Support Level | $5.12 | $1.41 |
| Resistance Level | $5.19 | $2.27 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 63.67 | 32.31 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.